Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001410830 XXXXXXXX LIVE 4 Common Stock, par value $0.00001 per share 05/07/2026 false 0001501796 05153U107 Aura Biosciences, Inc. 80 GUEST STREET BOSTON MA 02135 Joseph Downing 603-956-9145 Matrix Capital Management Company LP 3 Pleasant Street, Suite 400 Portsmouth NH 03801 Christopher Van Buren (212) 373-3000 Paul, Weiss, Rifkind, Wharton & Garrison 1285 Avenue of the Americas New York NY 10019 0001410830 N Matrix Capital Management Company LP OO N DE 0.00 0.00 0.00 0.00 0.00 N 0 IA PN Y David E. Goel OO N X1 0.00 0.00 0.00 0.00 0.00 N 0 IN HC Common Stock, par value $0.00001 per share Aura Biosciences, Inc. 80 GUEST STREET BOSTON MA 02135 The following constitutes Amendment No. 4 ("Amendment No. 4") to the Schedule 13D filed by the undersigned on November 4, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 filed by the undersigned with the Securities and Exchange Commission (the "SEC") on December 7, 2022 ("Amendment No. 1"), Amendment No. 2 filed by the undersigned with the SEC on November 9, 2023 ("Amendment No. 2"), and Amendment No. 3 filed by the undersigned with the Securities and Exchange Commission on May 19, 2025 ("Amendment No. 3" and the Original Schedule 13D as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3 and this Amendment No. 4, the "Schedule 13D"). This Amendment No. 4 amends and restates Item 5. Capitalized terms used herein and not otherwise defined in this Amendment No. 4 have the meanings set forth in the Schedule 13D. This Amendment No. 4 is the final amendment to the Schedule 13D and constitutes an "exit filing" for the Reporting Persons. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each Reporting Person. See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. On April 30, 2026, the Matrix Fund agreed to sell and the Issuer agreed to repurchase 6,922,870 shares of Common Stock from the Matrix Fund at a price of $5.64 per share, contingent upon the closing of a separate equity offering by the Issuer and certain other conditions (the "Repurchase"). The Repurchase closed on May 7, 2026. Except for the Repurchase, no transactions in the shares of Common Stock have been effected by the Reporting Persons during the past sixty (60) days. Not applicable May 7, 2026 Matrix Capital Management Company LP /s/ David E. Goel David E. Goel, Managing General Partner 05/11/2026 David E. Goel /s/ David E. Goel David E. Goel, Individually 05/11/2026